Global Scans · Pharmaceuticals · Weekly Summary

• [New] The second half of 2026 is expected to mark a major global regulatory approval window for innovative oncology therapies across leading pharmaceutical markets. demo4.wpbeginner.site
• [New] Abbott's worry is that if US policy excludes AI-generated outputs from protection, that could put a damper on future drug development. MIT Technology Review
• [New] While GLP-1 - analogous drugs have US Food and Drug Administration approval for type 2 diabetes and weight-loss treatment, they are not free of side effects or risks. New Atlas
• [New] Intismeran could be a blockbuster drug, reaching an average revenue of $1.4 billion by 2032. American Chemical Society
• [New] Global biologics manufacturing output is scaling sharply, with WHO projecting that biologics will account for over 30% of all approved drug products by 2028. Persistence Market Research
• [New] Escalating pharmaceutical trade tensions may create opportunities for Brazil's generic medicines sector as global manufacturers reassess export strategies. Fitch Solutions
• [New] Brazil's government consideration of pharmaceutical patents as a retaliatory tool against US tariffs will elevate intellectual property risks for innovative multinational drugmakers. Fitch Solutions
• [New] Moderate Growth Amid Strategic Restructuring And Pricing Pressures In 2026, pharmaceutical sales across most markets will exhibit moderate growth, driven by sustained demand and new product launches across most regions, though ongoing government cost containment pressures will constrain expansion. Fitch Solutions
• [New] Fastest-growing Region: Asia Pacific projected to expand at a CAGR of 5.6%, supported by government-led sustainability policies and growth in food and pharmaceutical packaging sectors. Persistence Market Research
• [New] As one of the Seven Key Global Biopharmaceutical Trends and Emerging Opportunities in 2026, AI is creating sustained growth opportunities across pharmaceutical ingredients, technology transfer, product licensing, regional distribution, and global commercialization partnerships. demo4.wpbeginner.site
• [New] Pharmaceuticals represent the fastest-growing end use segment, expanding at a CAGR of 8.2% between 2026 and 2033, driven by rising regulatory compliance requirements and growing automation investment across pharmaceutical manufacturing facilities worldwide. Persistence Market Research
• [New] Germany is anticipated to advance at 24.4% CAGR, owing to pharmaceutical export depth. FactMr
• [New] By Bioreactor Mode: Fed-batch is anticipated to capture 37.0% share in 2026 due to its broad use in monoclonal antibody and biosimilar production. FactMr
• [New] The Food and Drug Administration recently approved an updated COVID vaccine for people 65 and over, as well as for younger people who have a condition that increases their risk of severe illness from COVID. NewYork-Presbyterian
• [New] Researchers from the National University of Singapore's Yong Loo Lin School of Medicine (NUS Medicine) have discovered a drug that turns off a master switch driving tumour growth in triple-negative breast cancer, which could lead to better, more personalised treatments for the aggressive cancer. ST
• [New] Recent announcements of 100% (later 200%) tariffs on generics from 2028 onwards pose a significant risk to foreign suppliers and to patients. Coface
• Fastest Growing Region - Asia Pacific is set to register the highest CAGR through 2033, fueled by universal health coverage expansion, China's drug access reforms, India's generic drug manufacturing leadership, and rapid e-pharmacy growth across Southeast Asia. Persistence Market Research
• The pharmaceutical sector is projected to grow at a CAGR of 8.2% from 2026 to 2032, driven by rising demand for bioactive compounds derived from pork in nutraceuticals and specialty health products. 6wresearch
• The medical polymers industry was worth USD 20 billion in 2022 and is projected to grow at 8.3% each year until 2032, due to the rising demand for pharmaceutical devices. Global Market Insights Inc.
• Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think of, potentially speeding the race to new cures. MIT Technology Review
• The drug discovery & development segment is anticipated to register the fastest CAGR of 8.43% during 2026-2034. Straits Research
• As personalized medicine and biosimilar manufacturing scale globally, the demand for AI-enabled continuous bioprocessing platforms will intensify, positioning digital biomanufacturing solution providers at the center of a major manufacturing paradigm shift. Persistence Market Research

Last updated: 08 September 2026